| Document |
Document Title |
|
WO/2008/046598A1 |
The present invention provides a Compound of formula (I), wherein: R1 is a group selected from -CH2OH,-NH(CO)H; and R2 is a hydrogen atom; or R1 together with R2 form the group -NH-C(O)-CH=CH-, wherein the nitrogen atom is bound to the c...
|
|
WO/2008/045319A1 |
Sulfonate- or sulfate-capped, alkoxylated anti-misting agents having the structures: R((AO)nX)m((AO)nH)p and R3C(O)NH(CH2)2N+(CH3)2CH2CHR4CH2SO3 -, and to methods of suppressing mist from electrolyte solutions by adding a mist-suppressin...
|
|
WO/2008/042362A1 |
The present invention is directed to arylamino-arylpropanolamine derivatives of formula I: I or a pharmaceutically acceptable salt thereof, compositions containing these derivatives, and methods of their use for the prevention and treatm...
|
|
WO/2008/037590A1 |
The invention relates to a method for the continuous separation by distillation of mixtures that contain morpholine (MO), monoaminodiglycol (ADG), ammonia and water, obtained by reacting diethyleneglycol (DEG) with ammonia. The method ac...
|
|
WO/2008/038146A2 |
The invention relates generally to an improved process for manufacturing venlafaxine base and/or salts thereof.
|
|
WO/2008/037659A1 |
The invention relates to a method for producing electronic grade 2,2'-aminoethoxyethanol by reacting diethylene glycol with ammonia in a reactor in the presence of a catalyst, thereby obtaining a reaction mixture. A crude 2,2'-aminoethox...
|
|
WO/2008/035358A2 |
This invention relates to a new process for preparation of enantiomerically pure dapoxetine or an acid addition salt thereof i.e. S(+)-N,N-dimethyl-2-[2-(naphthalenyl oxy)ethyl]benzenemethanamine hydrochoride, a potent serotonin re-uptak...
|
|
WO/2008/035796A1 |
Disclosed is a method for producing a high-purity quaternary ammonium salt, which is characterized in that (1) an oxide or hydroxide of a group 1, 2, 12 or 13 metal is added into a quaternary ammonium salt which contains a protonic acid ...
|
|
WO/2008/032616A1 |
An oligoaniline compound represented by the formula (1) can provide a charge transporting thin film which shows a suppressed coloration in the visible range. Use of this thin film makes it possible to ensure a color reproducibility of a ...
|
|
WO/2008/030771A1 |
The present invention relates to novel compounds with a variety of therapeutic uses, more particularly novel substituted cyclic alkylidene compounds that are particularly useful for selective estrogen receptor modulation.
|
|
WO/2008/021533A2 |
Disclosed is a new ionic liquid monomer salt and methods of is synthesis and polymerization. The ionic liquid monomer salt is prepared by mixing equimolar amounts of an amine, such as tris[2-(2-methoxyethoxy)-ethyl]amine and an acid func...
|
|
WO/2008/022038A1 |
This disclosure concerns the discovery of (R,R)- and (R,S)-fenoterol analogues which are highly effective at binding β2-adrenergic receptors. Exemplary chemical structures for these analogues are provided. Also provided are pharmaceutic...
|
|
WO/2008/018447A1 |
Disclosed is an aminoalcohol derivative which is useful as an excellent immunosuppressant. Specifically disclosed is an aminoalcohol derivative represented by the general formula (1) below, which is a highly safe compound having excellen...
|
|
WO/2008/015240A1 |
The present invention is related to a family of N-phenyl-prenylamine derivatives of formula (I), and to their use in the treatment of cognitive, neurodegenerative or neuronal diseases or disorders, such as Alzheimer's disease or Parkinso...
|
|
WO/2008/015689A1 |
A process for the preparation of optically pure R (-) salbutamol of formula (6) and its pharmaceutically acceptable salts by using a (+) 4-nitro tartranilic acid as the resolving agent and a binary solvent system comprising alkyl acetate...
|
|
WO/2008/012283A1 |
The present invention relates to an improved process for the preparation of (2R,3R)-3- (3-methoxyphenyl)-N,N,2-trimethylpentanamine which is an intermediate for the preparation of the analgesic tapentadol.
|
|
WO/2008/012047A1 |
The present invention relates to a process for the preparation of (1 R,2R)-3- dimethylamino-1-ethyl-2-methyl-propyl)-phenol.
|
|
WO/2008/010764A2 |
The present invention relates to a novel process for the preparation of compounds of formula (V) wherein X, Q, R1, Rla and R2 are as defined in the specification, the compounds being useful in the preparation of therapeutic agents.
|
|
WO/2008/010481A1 |
[PROBLEMS] To provide a compound which can act as an NMDA antagonist having a wide safe range and is useful as a therapeutic agent or a prophylactic agent for Alzheimer's disease, cerebrovascular dementia, Parkinson's disease, ischemic s...
|
|
WO/2008/006749A1 |
The invention relates to a method for producing an amine by reacting a primary or secondary alcohol, aldehyde and/or ketone with hydrogen and a nitrogen compound, selected from the group comprising ammonia, primary and secondary amines, ...
|
|
WO/2008/006754A1 |
The invention relates to a method for producing an amine by reacting a primary or secondary alcohol, aldehyde and/or ketone with hydrogen and a nitrogen compound, selected from the group comprising ammonia, primary and secondary amines, ...
|
|
WO/2008/006750A1 |
The invention relates to a method for producing an amine by reacting a primary or secondary alcohol, aldehyde and/or ketone with hydrogen and a nitrogen compound, selected from the group comprising ammonia, primary and secondary amines, ...
|
|
WO/2008/006752A1 |
The invention relates to a method for producing an amine by reacting a primary or secondary alcohol, aldehyde and/or ketone with hydrogen and a nitrogen compound, selected from the group comprising ammonia, primary and secondary amines, ...
|
|
WO/2008/006627A1 |
The present invention relates to the compounds of formula (I), processes for their production and their use as anti-inflammatory agents.
|
|
WO/2008/005358A2 |
Described are antioxidant macromolecules and methods of making and using same.
|
|
WO/2008/004115A1 |
A process for preparing gabapentin of formula 1, which comprises Formula (I) converting 1-allyl-cyclohexanecarboxaldehyde into 1-allyl-cyclohexanecarbonitrile; ozonizing 1-allyl-cyclohexanecarbonitrile to obtain 1-cyano-cyclohexaneacetal...
|
|
WO/2008/002817A1 |
Certain substituted butyl and butynyl benzyl amine compounds are histamine H3 receptor and/or serotonin transporter modulators useful in the treatment of histamine H3 receptor- and/or serotonin-mediated diseases.
|
|
WO/2007/147866A1 |
The present invention generally relates to a process for preparing alkoxylated alkylamines and/or alkyl ether amines. The process consists of two stages and utilizes a catalyst with a multiple-charge counterion. The alkoxylated alkylamin...
|
|
WO/2007/148711A1 |
A compound represented by the formula (I) or a salt thereof, which is useful as an active ingredient of a pharmaceutical for the prevention and/or treatment of a disease induced by the activation of STAT6 and/or NF-κB. (I) wherein R1, R...
|
|
WO/2007/147564A1 |
The present invention belongs to the field of organic chemistry and refers to a process for the preparation of O-desmethylvenlafaxine (l-[2-Dimethylamino)-l-(4-hydroxyphenyl)ethyl]cyclo- hexanol), its analogues and pharmaceutical accepta...
|
|
WO/2007/140662A1 |
Combretastatin derivatives of formula (I) , preparation and use thereof are disclosed, wherein: Rf is alkyl with 1-8 carbon atoms and 1-17 fluorine atoms , R is amino, substituted amino, hydroxyl, nitro, halo, alkyloxy, phosphate or amin...
|
|
WO/2007/141593A2 |
The invention relates to an improved process for preparing metoprolol and its salts.
|
|
WO/2007/139923A1 |
Provided herein are substituted aminoglycidyl compounds of Formula (1), processes of preparation, and pharmaceutical compositions thereof and methods of their use for treating, preventing, or ameliorating one or more symptoms of a social...
|
|
WO/2007/134666A1 |
The invention relates to a compound of the following formula (I) X-CR1R2R3 wherein - R1 is an organic moiety having 6 to 24 carbon atoms; - R2 is H or an organic moiety having 6 to 24 carbon atoms; - R3 is X or OH; - X is a moiety of the...
|
|
WO/2007/134421A1 |
The present invention relates to the preparation of 2-vinyl indoles from ortho-gem-dibromovinylaniline compounds and alkene reagents using a palladium pre-catalyst, a base, and, in some instances, a ligand or additive. The present invent...
|
|
WO/2007/130704A1 |
The process of the present invention can be briefly summarized as depicted in the following scheme: R1is C1-Calkyl, R2 is C1-C6alkyl and Hal is a halogen atom.
|
|
WO/2007/126042A1 |
[PROBLEMS] To provide a novel compound having few adverse side-effects such as bradycardia and also having an excellent effect of reducing the number of lymphocytes in the peripheral blood. [MEANS FOR SOLVING PROBLEMS] Disclosed is a 2-a...
|
|
WO/2007/122579A2 |
A process for the preparation of 4-hydroxyalkylamino-2-nitro-anisoles of the general formula (I) wherein m is 2 or 3; by reaction of a 4-halogeno-3-nitro-aniline of formula (II) with a chloroalkyl-chloroformate, alkaline ring closure of ...
|
|
WO/2007/122847A1 |
A reagent for organic syntheses with which a chemical reaction can be conducted in a liquid phase and unnecessary compound(s) can be easily separated at low cost from the liquid phase after completion of the reaction. The reagent for org...
|
|
WO/2007/120923A1 |
Methods for preparing substantially pure O-desmethylvenlafaxine are described.
|
|
WO/2007/118818A1 |
The present invention refers to compounds of the formula (I) wherein X and R1 to R5 are defined as given in claim 1, as well as hair dye compositions containing them.
|
|
WO/2007/118964A1 |
The invention concerns polysubstituted N-(phenethyl)benzamide derivatives, pharmaceutical compositions containing same, as well as their therapeutic uses, in particular in the field of human and animal health. The invention also concerns...
|
|
WO/2007/117176A1 |
The invention relates to novel N-monomethyl-para methoxianiline, N,N-dimethyl-para methoxianiline, M-methyl-N-acetyl-para methoxianiline compounds exhibiting a high antiknock activity. Said para methoxianiline, N-acetyl-para methoxianili...
|
|
WO/2007/118041A1 |
Compounds are provided which bind to and are agonists, antagonists or inverse agonists of the CB2 receptor, the compounds having the general formula (I) wherein R1, R2, R3, X and Ar have the meanings given in the specification, and the p...
|
|
WO/2007/114213A1 |
[PROBLEMS] To provide a compound capable of inhibiting the production of a prostaglandin or leukotriene. [MEANS FOR SOLVING PROBLEMS] Disclosed is a compound represented by the general formula (I) or a salt thereof: (I) wherein (a) repre...
|
|
WO/2007/110548A1 |
The invention relates to a process of diastereoselective synthesis. This process carries out the diastereoselective alkylation of optically active nopinone to form the compound of formula (I) according to scheme A below, in which: R repr...
|
|
WO/2007/112358A1 |
The present invention provides a method for the synthesis of ß2-amino acids. The method also provides methods yielding a-substituted ß-amino aldehydes and ß-substituted γ-amino alcohols. The present method according to this invention...
|
|
WO/2007/107276A2 |
The present invention relates to a process for preparing C7 intermediates and their use in the preparation of pyrrole derivatives of a class that is effective at inhibiting the biosynthesis of cholesterol in humans, and more particularly...
|
|
WO/2007/107820A2 |
The invention concerns a process for the preparation of l-bromo-3- trif luoromethoxybenzene starting from 2- or 4-trif luoromethoxyaniline or a mixture of these compounds via a synthesis that provides excellent yields and surprising sele...
|
|
WO/2007/107282A1 |
Ethanolamine glyceryl ether condensation products of the formula (I) are described, in which R1, R2 and R3 may each independently be the same or different and are each hydrogen, a linear or branched, saturated alkyl chain having from 1 t...
|
